TY  - JOUR
AU  - Angelova, Assia Ludmilova
AU  - Barf, Milena
AU  - Just, Alexandra
AU  - Leuchs, Barbara
AU  - Rommelaere, Jean
AU  - Ungerechts, Guy
TI  - H-1 Parvovirus-Induced Oncolysis and Tumor Microenvironment Immune Modulation in a Novel Heterotypic Spheroid Model of Cutaneous T-Cell Lymphoma.
JO  - Cancers
VL  - 16
IS  - 15
SN  - 2072-6694
CY  - Basel
PB  - MDPI
M1  - DKFZ-2024-01644
SP  - 2711
PY  - 2024
N1  - #EA:D490#LA:D490#
AB  - The rat protoparvovirus H-1 (H-1PV) is an oncolytic virus known for its anticancer properties in laboratory models of various human tumors, including non-Hodgkin lymphomas (NHL) of B-cell origin. However, H-1PV therapeutic potential against hematological malignancies of T-cell origin remains underexplored. The aim of the present study was to conduct a pilot preclinical investigation of H-1PV-mediated oncolytic effects in cutaneous T-cell lymphoma (CTCL), a type of NHL that is urgently calling for innovative therapies. We demonstrated H-1PV productive infection and induction of oncolysis in both classically grown CTCL suspension cultures and in a novel, in vivo-relevant, heterotypic spheroid model, but not in healthy donor controls, including peripheral blood mononuclear cells (PBMCs). H-1PV-mediated oncolysis of CTCL cells was not prevented by Bcl-2 overexpression and was accompanied by increased extracellular ATP release. In CTCL spheroid co-cultures with PBMCs, increased spheroid infiltration with immune cells was detected upon co-culture treatment with the virus. In conclusion, our preclinical data show that H-1PV may hold significant potential as an ingenious viroimmunotherapeutic drug candidate against CTCL.
KW  - cutaneous T-cell lymphoma (CTCL) (Other)
KW  - heterotypic CTCL spheroid (Other)
KW  - oncolytic H-1 parvovirus (Other)
KW  - virotherapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:39123440
C2  - pmc:PMC11311363
DO  - DOI:10.3390/cancers16152711
UR  - https://inrepo02.dkfz.de/record/292156
ER  -